#USA #Dallas #Ulcerative Colitis #Loopback Analytics #NASP Annual Meeting

Loopback Analytics Achieves Recognition at NASP Annual Meeting

Dallas-based Loopback Analytics has announced a significant achievement at the recent National Association of Specialty Pharmacy (NASP) Annual Meeting. The company was awarded the prestigious Attendee Choice Poster Award for their exemplary research poster titled "Identification of a Feasible, Evidence-Based Approach to Ulcerative Colitis Disease Assessment by Specialty Pharmacies."

This research conducted by Loopback delves into vital findings on inflammatory bowel disease (IBD), focusing specifically on ulcerative colitis. The project was carried out in collaboration with gastroenterology clinical pharmacists from top academic medical centers within Loopback's extensive network. The objective was to discover practical, evidence-based methodologies for assessing disease activity in patients suffering from ulcerative colitis.

The research encompassed three core components:

1. Literature Review: The investigation commenced with an extensive review of recommended tools for assessing the disease. This review provided a foundational understanding of existing methods and highlighted their importance.

2. Real-World Data Analysis: Leveraging their vast network, Loopback executed an analysis on the practical application of these assessment tools in real-world settings. This data revealed discrepancies in how these tools are utilized in practice, revealing a critical gap in standardized assessment.

3. Consultation with Experts: An evidence council, comprised of GI clinical pharmacists from Loopback’s network, contributed insights regarding existing barriers, potential opportunities, and strategies for the adoption of standardized assessments in practice.

The findings underscored an essential observation: while structured tools like the Mayo Score are frequently referenced in literature, their application varies significantly across different healthcare settings. Often, healthcare providers rely heavily on subjective symptoms, such as rectal bleeding, emphasizing the pressing need for specialty pharmacies within academic medical environments to help create consistency in assessments. Such standardization can significantly enhance the quality of care and support the treat-to-target approach in managing ulcerative colitis.

Neil Smiley, CEO of Loopback Analytics, expressed his enthusiasm regarding the implications of this research, stating, "This work affirms the impact of Loopback's network in surfacing real-world insights that guide improvements in specialty care. By combining evidence, data, and the GI expertise of pharmacists across leading academic medical centers, together we can identify gaps and advance solutions that improve outcomes for patients."

The award-winning poster was co-authored by a proficient team, including Megan Rees, PharmD, BCACP, CSP; Michael Gannon, PharmD, MBA; and Samuel Konstanty from Loopback Analytics, along with Samantha Mehta, PharmD, and Jason Lynn, PharmD from Pfizer Medical Affairs. Their collaboration reflects a deep-seated commitment to standardizing disease assessments, enhancing population health management, and ultimately improving patient outcomes in the field of gastroenterology.

Loopback Analytics is renowned for partnering with pharmaceutical manufacturers to bring pharmacists together across their network, focusing on research that yields real-world evidence to enhance patient outcomes. Interested parties can connect with Loopback Analytics to explore collaboration opportunities at www.loopbackanalytics.com.

In summary, Loopback Analytics’ recognition at the NASP Annual Meeting marks an essential step in addressing the challenges of assessing ulcerative colitis effectively. By promoting standardized assessment practices, Loopback is paving the way for improved patient care and outcomes in specialty pharmacy and beyond.